Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $229
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.